| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of GFAP-astroglial autoimmunity presenting with reversible parkinsonism
|
Tomczak, Anna
|
|
|
39 |
C |
p.
|
artikel
|
| 2 |
Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months
|
Pytel, Vanesa
|
|
|
39 |
C |
p.
|
artikel
|
| 3 |
Assessing life balance of European people with multiple sclerosis: A multicenter clinimetric study within the RIMS network
|
Kos, Daphne
|
|
|
39 |
C |
p.
|
artikel
|
| 4 |
Autoimmune glial fibrillary acidic protein astrocytopathy resulting in treatment-refractory flaccid paralysis
|
Allen, Alexander
|
|
|
39 |
C |
p.
|
artikel
|
| 5 |
Big pharma and social responsibility
|
Hawkes, Christopher H.
|
|
|
39 |
C |
p.
|
artikel
|
| 6 |
Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab
|
Raquel, Calle-Calle
|
|
|
39 |
C |
p.
|
artikel
|
| 7 |
Clinical instrument to retrospectively capture levels of EDSS
|
Ciotti, John Robert
|
|
|
39 |
C |
p.
|
artikel
|
| 8 |
Comparison of the effects of two different exergaming systems on balance, functionality, fatigue, and quality of life in people with multiple sclerosis: A randomized controlled trial
|
Yazgan, Yonca Zenginler
|
|
|
39 |
C |
p.
|
artikel
|
| 9 |
Correlations of health status indicators with perceived neuropsychological impairment and cognitive processing speed in multiple sclerosis
|
D'hooghe, Marie B.
|
|
|
39 |
C |
p.
|
artikel
|
| 10 |
Cross cultural adaptation and psychometric evaluation of an Arabic version of the modified fatigue impact scale in people with multiple sclerosis
|
Khalil, Hanan
|
|
|
39 |
C |
p.
|
artikel
|
| 11 |
Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases
|
Ma, SB
|
|
|
39 |
C |
p.
|
artikel
|
| 12 |
Disease activity impacts disability progression in primary progressive multiple sclerosis
|
Marrodan, M.
|
|
|
39 |
C |
p.
|
artikel
|
| 13 |
Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?
|
Rojas, Juan Ignacio
|
|
|
39 |
C |
p.
|
artikel
|
| 14 |
Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial
|
Messinis, Lambros
|
|
|
39 |
C |
p.
|
artikel
|
| 15 |
Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β
|
Buron, Mathias Due
|
|
|
39 |
C |
p.
|
artikel
|
| 16 |
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
|
Lotan, Itay
|
|
|
39 |
C |
p.
|
artikel
|
| 17 |
Factors associated with therapeutic inertia among pharmacists caring for people with multiple sclerosis
|
Terzaghi, Maria A.
|
|
|
39 |
C |
p.
|
artikel
|
| 18 |
Identification of Multiple Sclerosis key genetic factors through multi-staged data mining
|
Navaderi, Mohammad
|
|
|
39 |
C |
p.
|
artikel
|
| 19 |
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials
|
Riester, Katherine
|
|
|
39 |
C |
p.
|
artikel
|
| 20 |
Impairments of humour comprehension in multiple sclerosis
|
Ehrlé, Nathalie
|
|
|
39 |
C |
p.
|
artikel
|
| 21 |
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab
|
Ziemssen, Tjalf
|
|
|
39 |
C |
p.
|
artikel
|
| 22 |
Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis
|
Pietroboni, Anna M.
|
|
|
39 |
C |
p.
|
artikel
|
| 23 |
Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment
|
Borhani-Haghighi, Afshin
|
|
|
39 |
C |
p.
|
artikel
|
| 24 |
Neurofibromatosis type 2 and multiple sclerosis
|
Helbing, Dario-Lucas
|
|
|
39 |
C |
p.
|
artikel
|
| 25 |
NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity
|
Peng, Yu
|
|
|
39 |
C |
p.
|
artikel
|
| 26 |
No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a
|
Freedman, Mark S.
|
|
|
39 |
C |
p.
|
artikel
|
| 27 |
Obesity, dieting, and multiple sclerosis
|
Russell, R.D.
|
|
|
39 |
C |
p.
|
artikel
|
| 28 |
Objective sensor-based gait measures reflect motor impairment in multiple sclerosis patients: Reliability and clinical validation of a wearable sensor device
|
Flachenecker, Felix
|
|
|
39 |
C |
p.
|
artikel
|
| 29 |
Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review
|
Visser, L.A.
|
|
|
39 |
C |
p.
|
artikel
|
| 30 |
Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients
|
Giacomini, Thea
|
|
|
39 |
C |
p.
|
artikel
|
| 31 |
Photoreceptor outer nuclear layer thickness changes in optic neuritis follow up
|
Fard, Masoud Aghsaei
|
|
|
39 |
C |
p.
|
artikel
|
| 32 |
Prevalence of self-reported language impairment in multiple sclerosis and the association with health-related quality of life: An international survey study
|
El-Wahsh, Sarah
|
|
|
39 |
C |
p.
|
artikel
|
| 33 |
QKI-V5 is downregulated in CNS inflammatory demyelinating diseases
|
Lavon, Iris
|
|
|
39 |
C |
p.
|
artikel
|
| 34 |
Relative importance of vision and proprioception in maintaining standing balance in people with multiple sclerosis
|
Yang, Feng
|
|
|
39 |
C |
p.
|
artikel
|
| 35 |
Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody
|
Kojima, Miki
|
|
|
39 |
C |
p.
|
artikel
|
| 36 |
Thalamo-cortical dysfunction contributes to fatigability in multiple sclerosis patients: A neurophysiological study
|
Capone, Fioravante
|
|
|
39 |
C |
p.
|
artikel
|
| 37 |
The COVID-19 pandemic and the use of MS disease-modifying therapies
|
Giovannoni, Gavin
|
|
|
39 |
C |
p.
|
artikel
|
| 38 |
The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis
|
Lorefice, Lorena
|
|
|
39 |
C |
p.
|
artikel
|
| 39 |
The role of the clinical nurse specialist multiple sclerosis, the patients’ and families’ and carers’ perspective: An integrative review
|
MEEHAN, Michelle
|
|
|
39 |
C |
p.
|
artikel
|
| 40 |
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis
|
Foley, John
|
|
|
39 |
C |
p.
|
artikel
|
| 41 |
To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis
|
Bsteh, Gabriel
|
|
|
39 |
C |
p.
|
artikel
|
| 42 |
Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: A case report
|
Ashtari, Fereshteh
|
|
|
39 |
C |
p.
|
artikel
|
| 43 |
Validation of 0–10 MS symptom scores in the Australian multiple sclerosis longitudinal study
|
Zhang, Yan
|
|
|
39 |
C |
p.
|
artikel
|
Tijdschrift beschrijving